Updated:
Be The Match BioTherapies
Be The Match BioTherapies originated as the commercial products division of the National Marrow Donor Program (NMDP) in 1987.
Be The Match BioTherapies
Be The Match BioTherapies originated as the commercial products division of the National Marrow Donor Program (NMDP) in 1987. The NMDP, based in Minneapolis, runs the Be The Match Registry, the world's most diverse donor registry, and its commercial arm provides specialized cell-therapy products and services to pharmaceutical and biotech companies. The firm offers a suite of services including cell sourcing, apheresis collection, chain-match donor coordination, and graft-versus-host disease research development. It partners with companies developing CAR-T therapies, gene therapies, and other cell-based treatments. Known clients include Juno Therapeutics, Kite Pharma (a Gilead company), and bluebird bio, though exact deal terms and revenues are not public. The organization operates from five offices across the US — Minneapolis (HQ), Mountain View, Cambridge, Somerville, and Boston. In 2023, NMDP reported over 60,000 cell transplants facilitated globally. Amy Ronneberg, president of Be The Match BioTherapies, has led the unit since 2015. As a nonprofit subsidiary, Be The Match BioTherapies reinvests operating surpluses into the NMDP registry and patient access programs. This structure — a commercial services group inside a public-health nonprofit — is uncommon in the biotech sector and gives it a mission-aligned mandate rather than a profit-maximization objective.
General information
Firm type
other
Year founded
1987
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Minneapolis
Corporate office
Minneapolis, MN, United States
Additional offices
Mountain View, CA · Cambridge, MA · Somerville, MA · Boston, MA
Principals
Amy Ronneberg
President
Sector focus
Frequently asked questions
Who runs Be The Match BioTherapies?
Amy Ronneberg has served as president of Be The Match BioTherapies since 2015, according to the organization's official communications. She previously held leadership roles within the National Marrow Donor Program.
How is Be The Match BioTherapies structured — is it a family office?
No — it is the commercial services subsidiary of the National Marrow Donor Program, a nonprofit organization. It is not a single-family office or investment vehicle. It operates as a mission-driven business unit within a public-health infrastructure entity.
What services does Be The Match BioTherapies provide to biotech firms?
It provides cell sourcing and procurement, apheresis collection, donor registry access, chain-match coordination for transplant logistics, and research services related to graft-versus-host disease. Its primary value is facilitating access to a diverse donor pool of over 41 million registered donors.
Which biotech companies does Be The Match BioTherapies work with?
Publicly known collaborations include Juno Therapeutics, Kite Pharma (a Gilead company), and bluebird bio. The firm works with many cell and gene therapy developers but does not typically disclose the full list of clients due to confidentiality agreements.
What is the relationship between Be The Match BioTherapies and the National Marrow Donor Program?
Be The Match BioTherapies is wholly owned by the NMDP and operates as its commercial arm. All surpluses from its services are reinvested into the NMDP's core mission of maintaining and growing the Be The Match registry, funding patient access programs, and supporting transplant research.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: